Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study

by divibasicbldev | Nov 20, 2025 | Press Releases

— Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months — — A second MEK-rechallenge 3rd-line melanoma patient with BRAF V600E...

Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

by divibasicbldev | Nov 4, 2025 | Press Releases

Platinum sponsorship of NF Caregivers Symposium reinforces commitment to NF1 communityMIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company...

Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients

by divibasicbldev | Sep 16, 2025 | Press Releases

First patient in South Korea dosedMIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic...

Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

by divibasicbldev | Sep 8, 2025 | Press Releases

— Recommendation that trial escalate to next dose level of 8mg tablet — — Initial interim clinical data from first two cohorts expected in Q1 2026 — MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA)...

Pasithea Therapeutics Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

by divibasicbldev | Aug 29, 2025 | Press Releases

MIAMI, Aug. 29, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced...

Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

by divibasicbldev | Aug 28, 2025 | Press Releases

MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced...